Entry Inhibitors in HIV Therapy

Entry Inhibitors in HIV Therapy details the current status of this relatively new and very dynamic class of inhibitors, appealing to both the clinician and basic research scientist. A unique overview of obstacles and accomplishments is presented. The book features chapters that explain the challenges of high sequence diversity in the viral envelope gene for the development and use of entry inhibitors, the clinical utility of virus phenotyping, the development of this class of inhibitors as microbicidal therapy, and the success story of enfuvirtide from the bench to FDA approval. Both basic research findings and results of clinical studies are covered and linked together by a diverse panel of experts in the field.

The impact of viral sequence diversity on this class of inhibitors is discussed Connection between basic research and clinical studies is shown Focuses on real-world issues, such as virus phenotyping in the clinic Unique collection of contributors from basic research, pharmaceutical research, and the clinic Includes supplementary material: sn.pub/extras

Klappentext

Entry Inhibitors in HIV Therapy presents the current status of this relatively new and highly dynamic class of inhibitors and provides a unique overview of obstacles and considerations for HIV entry inhibition compared to other antiretroviral targets.

The introductory chapters of this book present an overview of entry inhibitors, review current knowledge of how Env mediates entry, and discuss the challenge of genetic diversity in this region of the viral genome. Subsequent chapters feature current information on individual classes of entry inhibitors that target each step of the virus entry pathway, from attachment to membrane fusion. There is an emphasis on the complex determinants of entry inhibitor susceptibility, resistance mechanisms, the need for clinical phenotyping, and how these issues create new challenges for antiretroviral therapy. Encouraging pre-clinical studies of entry inhibitors as microbicidesare also discussed. The final chapters highlight the current status of entry inhibitors in clinical studies, the major milestone achieved with FDA approval of enfuvirtide, and review drug development, past and present.

In summary, this book presents a comprehensive and current overview of entry inhibitors from an expert panel of authors with diverse backgrounds and perspectives, incorporating many unrelenting successes against a backdrop of formidable challenges. It is of interest to basic science researchers as well as clinical physicians.

Inhalt
to entry inhibitors in the management of HIV infection.- The challenge of HIV sequence diversity in the envelope glycoprotein.- Attachment of human immunodeficiency virus to cells and its inhibition.- Inhibitors that target gp120-CD4 interactions.- Inhibitors that target gp120 interactions with coreceptor.- Inhibitors that target fusion.- HIV-1 entry inhibitors as microbicides.- Entry inhibition of HIV-1 subtype C isolates.- The utility of coreceptor typing in the clinic.- Future clinical prospects for entry inhibitors.- Enfuvirtide: from basic science to FDA approval.- Targets for drug development past and present.